KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 81 filers reported holding KEROS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71,284 | -4.6% | 2,236 | +20.3% | 0.00% | 0.0% |
| Q2 2023 | $74,695 | +24.0% | 1,859 | +31.8% | 0.00% | +50.0% |
| Q1 2023 | $60,250 | -16.8% | 1,411 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $72,455 | +36.7% | 1,411 | 0.0% | 0.00% | +50.0% |
| Q3 2022 | $53,000 | +76.7% | 1,411 | +29.2% | 0.00% | +100.0% |
| Q2 2022 | $30,000 | -49.2% | 1,092 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $59,000 | -7.8% | 1,092 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $64,000 | +48.8% | 1,092 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $43,000 | -6.5% | 1,092 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $46,000 | -31.3% | 1,092 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $67,000 | -13.0% | 1,092 | 0.0% | 0.00% | -25.0% |
| Q4 2020 | $77,000 | +220.8% | 1,092 | +77.6% | 0.00% | +300.0% |
| Q3 2020 | $24,000 | +4.3% | 615 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $23,000 | – | 615 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |